<DOC>
	<DOC>NCT01311635</DOC>
	<brief_summary>The purpose of this study is to study the relative bioavailability of AZD1981 when using a new tablet compared to the current tablet.</brief_summary>
	<brief_title>A Bioavailability Study Comparing 3 Different AZD1981 Tablets</brief_title>
	<detailed_description />
	<criteria>Healthy male and postmenopausal or surgically sterile female volunteers aged 1855, inclusive Have a body mass index between 1930 kg/m2 and weigh at least 50 kg and no more than 100 kg, inclusive Be a nonsmoker or exsmoker who has stopped smoking for &gt;6 months prior to screening Volunteers must be willing to use barrier methods of contraceptive, unless their partners are postmenopausal, surgically sterile or using accepted contraceptive methods. Any clinically significant disease or disorder Any clinically relevant abnormal findings in the physical examination, clinical chemistry, haematology, urinalysis, vital signs (including body temperature), or ECG assessments at Visit 1, or in vital signs (including body temperature) at Visit 2 Prolonged QTcF &gt;450 ms or shortened QTcF&lt;340 ms at Visit 1 or family history of long QT syndrome History of, or current alcohol or drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>bioavailability study</keyword>
	<keyword>AZD1981</keyword>
	<keyword>tablets</keyword>
	<keyword>To study the relative bioavailability of single dose AZD1981 via three different tablets</keyword>
	<keyword>To compare the bioavailability between three different AZD1981 tablets</keyword>
</DOC>